Lymphocyte-dependent antibody-mediated cytolysis of DNA-anti-DNA-coated target cells using human and murine SLE effector populations

M. Eric Gershwin, Weislaw Glinski, Thomas Chused, Alfred D. Steinberg

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The ability of peripheral blood lymphocytes (PBL), T cells, B cells, and monocytes from normal volunteers as well as from patients with SLE, chronic lymphocytic leukemia (CLL), and Sezary syndrome to function as effector cells in a lymphocyte-dependent antibody-mediated cytolytic (LDAMC) process, using DNA-anti-DNA-coated sheep red blood cells as targets, was studied. Both normal peripheral blood B cells and monocytes functioned well in this assay at an effector to target ratio of 10:1 using as little as a 10-5 dilution of antibody. In contrast, peripheral blood T cells as well as cells from patients with CLL and Sezary syndrome were ineffective. PBL derived from patients with inactive SLE were similar to normal PBL in this assay. However, PBL from patients with active SLE had little effector activity at low effector to target cell ratios. At high effector to target cell ratios this decreased efficiency was less marked. Unlike human PBL, spleen cells from New Zealand and BALB/c mice functioned only at effector to target cell ratios of > 50:1. Moreover, with age, a significant decrease in the ability of New Zealand, but not BALB/c, spleen cells to function in this assay was noted. As with other LDAMC systems, the reaction was mediated by IgG antibody and was inhibited by aggregated human γ-globulin. Although LDAMC appears depressed in both patients and mice with active SLE, we suggest the possibility that LDAMC of immune complex-coated cells/tissue may be an additional mediator of tissue injury.

Original languageEnglish (US)
Pages (from-to)280-291
Number of pages12
JournalClinical Immunology and Immunopathology
Volume8
Issue number2
DOIs
StatePublished - 1977

Fingerprint

Lymphocytes
Antibodies
DNA
Population
Sezary Syndrome
B-Cell Chronic Lymphocytic Leukemia
New Zealand
Monocytes
Blood Cells
B-Lymphocytes
Spleen
T-Lymphocytes
Globulins
Antigen-Antibody Complex
Sheep
Healthy Volunteers
Immunoglobulin G
Erythrocytes
Wounds and Injuries

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Lymphocyte-dependent antibody-mediated cytolysis of DNA-anti-DNA-coated target cells using human and murine SLE effector populations. / Gershwin, M. Eric; Glinski, Weislaw; Chused, Thomas; Steinberg, Alfred D.

In: Clinical Immunology and Immunopathology, Vol. 8, No. 2, 1977, p. 280-291.

Research output: Contribution to journalArticle

@article{f8168bcdaba04138b65e1e81d3bafdd7,
title = "Lymphocyte-dependent antibody-mediated cytolysis of DNA-anti-DNA-coated target cells using human and murine SLE effector populations",
abstract = "The ability of peripheral blood lymphocytes (PBL), T cells, B cells, and monocytes from normal volunteers as well as from patients with SLE, chronic lymphocytic leukemia (CLL), and Sezary syndrome to function as effector cells in a lymphocyte-dependent antibody-mediated cytolytic (LDAMC) process, using DNA-anti-DNA-coated sheep red blood cells as targets, was studied. Both normal peripheral blood B cells and monocytes functioned well in this assay at an effector to target ratio of 10:1 using as little as a 10-5 dilution of antibody. In contrast, peripheral blood T cells as well as cells from patients with CLL and Sezary syndrome were ineffective. PBL derived from patients with inactive SLE were similar to normal PBL in this assay. However, PBL from patients with active SLE had little effector activity at low effector to target cell ratios. At high effector to target cell ratios this decreased efficiency was less marked. Unlike human PBL, spleen cells from New Zealand and BALB/c mice functioned only at effector to target cell ratios of > 50:1. Moreover, with age, a significant decrease in the ability of New Zealand, but not BALB/c, spleen cells to function in this assay was noted. As with other LDAMC systems, the reaction was mediated by IgG antibody and was inhibited by aggregated human γ-globulin. Although LDAMC appears depressed in both patients and mice with active SLE, we suggest the possibility that LDAMC of immune complex-coated cells/tissue may be an additional mediator of tissue injury.",
author = "Gershwin, {M. Eric} and Weislaw Glinski and Thomas Chused and Steinberg, {Alfred D.}",
year = "1977",
doi = "10.1016/0090-1229(77)90118-0",
language = "English (US)",
volume = "8",
pages = "280--291",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Lymphocyte-dependent antibody-mediated cytolysis of DNA-anti-DNA-coated target cells using human and murine SLE effector populations

AU - Gershwin, M. Eric

AU - Glinski, Weislaw

AU - Chused, Thomas

AU - Steinberg, Alfred D.

PY - 1977

Y1 - 1977

N2 - The ability of peripheral blood lymphocytes (PBL), T cells, B cells, and monocytes from normal volunteers as well as from patients with SLE, chronic lymphocytic leukemia (CLL), and Sezary syndrome to function as effector cells in a lymphocyte-dependent antibody-mediated cytolytic (LDAMC) process, using DNA-anti-DNA-coated sheep red blood cells as targets, was studied. Both normal peripheral blood B cells and monocytes functioned well in this assay at an effector to target ratio of 10:1 using as little as a 10-5 dilution of antibody. In contrast, peripheral blood T cells as well as cells from patients with CLL and Sezary syndrome were ineffective. PBL derived from patients with inactive SLE were similar to normal PBL in this assay. However, PBL from patients with active SLE had little effector activity at low effector to target cell ratios. At high effector to target cell ratios this decreased efficiency was less marked. Unlike human PBL, spleen cells from New Zealand and BALB/c mice functioned only at effector to target cell ratios of > 50:1. Moreover, with age, a significant decrease in the ability of New Zealand, but not BALB/c, spleen cells to function in this assay was noted. As with other LDAMC systems, the reaction was mediated by IgG antibody and was inhibited by aggregated human γ-globulin. Although LDAMC appears depressed in both patients and mice with active SLE, we suggest the possibility that LDAMC of immune complex-coated cells/tissue may be an additional mediator of tissue injury.

AB - The ability of peripheral blood lymphocytes (PBL), T cells, B cells, and monocytes from normal volunteers as well as from patients with SLE, chronic lymphocytic leukemia (CLL), and Sezary syndrome to function as effector cells in a lymphocyte-dependent antibody-mediated cytolytic (LDAMC) process, using DNA-anti-DNA-coated sheep red blood cells as targets, was studied. Both normal peripheral blood B cells and monocytes functioned well in this assay at an effector to target ratio of 10:1 using as little as a 10-5 dilution of antibody. In contrast, peripheral blood T cells as well as cells from patients with CLL and Sezary syndrome were ineffective. PBL derived from patients with inactive SLE were similar to normal PBL in this assay. However, PBL from patients with active SLE had little effector activity at low effector to target cell ratios. At high effector to target cell ratios this decreased efficiency was less marked. Unlike human PBL, spleen cells from New Zealand and BALB/c mice functioned only at effector to target cell ratios of > 50:1. Moreover, with age, a significant decrease in the ability of New Zealand, but not BALB/c, spleen cells to function in this assay was noted. As with other LDAMC systems, the reaction was mediated by IgG antibody and was inhibited by aggregated human γ-globulin. Although LDAMC appears depressed in both patients and mice with active SLE, we suggest the possibility that LDAMC of immune complex-coated cells/tissue may be an additional mediator of tissue injury.

UR - http://www.scopus.com/inward/record.url?scp=0017704454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017704454&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(77)90118-0

DO - 10.1016/0090-1229(77)90118-0

M3 - Article

C2 - 71226

AN - SCOPUS:0017704454

VL - 8

SP - 280

EP - 291

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -